Regeneron’s COVID-19 Vaccine Enters Phase 3 Of Trials

July 7, 2020

A COVID-19 Vaccine is set to start late stage trials where they can test to see how well the the drug works to not only treat, but prevent the coronavirus.

Biotech company Regeneron has said that they have a unique double antibody solution during a press release on Monday.

This vaccine is unique because it claims to be able to prevent infection for people who have been in close contact with someone who’s infected, like a housemate. The trial is currently in phase 3 and will be conducted in 100 sites with around 2,000 subjects in the United States.

Dr. George D. Yancopoulos, co founder, president and chief scientific officer of Regeneron said:

“We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic.”


Similar Articles